UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

Annals of oncology, 2023-12, Vol.34 (12), p.1131-1140

2023

Volltextzugriff (PDF)

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

European journal of cancer (1990), 2020-10, Vol.138, p.S1-S2

2020

Volltextzugriff (PDF)

Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers

Annals of oncology, 2018-10, Vol.29, p.viii408-viii409

2018

Volltextzugriff (PDF)

Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)

Annals of oncology, 2018-06, Vol.29, p.v66-v66

2018

Volltextzugriff (PDF)

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

ESMO open, 2024-07, Vol.9 (7), p.103625, Article 103625

2024

Volltextzugriff (PDF)

Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii138

2018

Volltextzugriff (PDF)

Interim results from a phase I trial of SL-801: A novel XPO-1 inhibitor, in patients with advanced solid tumors

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii140

2018

Volltextzugriff (PDF)

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii496-viii497

2018

Volltextzugriff (PDF)

Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

Annals of oncology, 2018-10, Vol.29, p.viii736-viii736

2018

Volltextzugriff (PDF)

Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy

Annals of oncology, 2018-10, Vol.29, p.viii451-viii452

2018

Volltextzugriff (PDF)

Cloning and characterization of the mating type ( MAT) locus from Ascochyta rabiei (teleomorph: Didymella rabiei) and a MAT phylogeny of legume-associated Ascochyta spp

Fungal genetics and biology, 2003-07, Vol.39 (2), p.151-167

2003

Volltextzugriff (PDF)

Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: Preliminary results

Gynecologic oncology, 2015-04, Vol.137, p.2-3

2015

Volltextzugriff (PDF)

Immune response and survival of refractory cancer patients who received TGF- beta 2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine

Gene therapy, 2013-09, Vol.20 (9), p.875-879

2013

Volltextzugriff (PDF)

Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine

Gene therapy, 2013-09, Vol.20 (9), p.875-879

2013

Volltextzugriff (PDF)

Potential of microsatellites to distinguish four races of Fusarium oxysporum f. sp. ciceri prevalent in India

Theoretical and applied genetics, 2001-01, Vol.102 (1), p.138-147

2001

Volltextzugriff (PDF)

79TiP A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

Annals of oncology, 2022-04, Vol.33, p.S69-S70

2022

Volltextzugriff (PDF)

A pharmacoeconomic study of different brands of commonly prescribed antihypertensive drugs

International journal of basic and clinical pharmacology, 2021-08, Vol.10 (8), p.976

2021

Volltextzugriff (PDF)

Assessment of comorbidities in patients with deranged thyroid hormone levels

International journal of basic and clinical pharmacology, 2020-07, Vol.9 (7), p.1044

2020

Volltextzugriff (PDF)

Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type

American journal of clinical pathology, 2024-10, Vol.162 (Supplement_1), p.S127-S127

2024

Volltextzugriff (PDF)

665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation

Annals of oncology, 2023-10, Vol.34, p.S468-S468

2023

Volltextzugriff (PDF)

1375P Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data

Annals of oncology, 2023-10, Vol.34, p.S789-S790

2023

Volltextzugriff (PDF)

MA12.10 Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S105-S105

2024

Volltextzugriff (PDF)

514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

European journal of cancer (1990), 2024-10, Vol.211, p.114992, Article 114992

2024

Volltextzugriff (PDF)

1 – 25 von 488

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(424)
Mit Volltextzugriff
(414)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers

Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors

Interim results from a phase I trial of SL-801: A novel XPO-1 inhibitor, in patients with advanced solid tumors

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy

Cloning and characterization of the mating type ( MAT) locus from Ascochyta rabiei (teleomorph: Didymella rabiei) and a MAT phylogeny of legume-associated Ascochyta spp

Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: Preliminary results

Immune response and survival of refractory cancer patients who received TGF- beta 2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine

Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine

Potential of microsatellites to distinguish four races of Fusarium oxysporum f. sp. ciceri prevalent in India

79TiP A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

A pharmacoeconomic study of different brands of commonly prescribed antihypertensive drugs

Assessment of comorbidities in patients with deranged thyroid hormone levels

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation

1375P Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data

MA12.10 Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial

514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

Suchergebnisse filtern